文献速递儿童心血管与肾脏儿童呼吸

靶向生物抑制辅助治疗儿童多血管腔内肺静脉狭窄

Adjunct Targeted Biologic Inhibition Agents to Treat Aggressive Multivessel Intraluminal Pediatric Pulmonary Vein Stenosis.
PubMed 文献 · J Pediatr · 2018-03-23

这项单臂前瞻性开放标签试验评估伊马替尼联合或不联合贝伐珠单抗作为介入治疗辅助手段,用于治疗儿童多血管腔内肺静脉狭窄(PVS)。48例患者中,72周随访时16例稳定、27例局部复发未稳定、5例进展;72周生存率为77%(37/48),药物相关毒性轻微。

要点

  • 72周生存率77%,16/48例稳定,27例局部复发未稳定,5例进展。
  • 稳定与无肺病(P=.03)及较高合格药物剂量百分比(P=.03)相关。
  • 药物相关不良事件仅16例,均非严重,酪氨酸激酶抑制毒性轻微。

核心结论

  • 在转诊的多血管腔内PVS患者中,采用包括抗增殖酪氨酸激酶阻断在内的多模式治疗,72周生存率为77%。
  • 酪氨酸激酶阻断特异性毒性轻微。

研究设计与样本

  • 单臂、前瞻性、开放标签、美国FDA批准的试验,纳入2009年3月至2014年12月间≥2条肺静脉受累且在手术或导管解除梗阻后的患者。
  • 共48例患者入组,其中5例孤立性PVS、26例先天性心脏病、5例肺病、12例两者兼有。
  • 药物治疔在48周或稳定24周后停药,以较晚者为准。

主要发现

  • 72周随访后,16例稳定、27例局部复发未稳定、5例进展。
  • 稳定与无肺病(P=.03)和较高合格药物剂量百分比(P=.03)相关,与年龄、诊断、病变侧别或受累静脉数量无关。
  • 72周生存率为77%(37/48)。
  • 不良事件常见(共1489例次),但仅16例肯定与药物治疗相关,均非严重。

临床怎么用

  • 对于多血管腔内PVS患者,可考虑在介入治疗基础上辅以靶向酪氨酸激酶抑制(伊马替尼联合或不联合贝伐珠单抗)。
  • 治疗期间需关注药物剂量完成情况,较高合格药物剂量百分比与稳定相关。
  • 无肺病患者可能更易从靶向辅助治疗中获益。

局限性

  • 单臂、开放标签设计,无对照组,无法明确因果效应。
  • 样本量较小(48例),来自转诊人群,结果外推需谨慎。
  • 不良事件常见但药物相关严重事件少,长期安全性数据未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the use of imatinib mesylate with or without bevacizumab targeting neoproliferative myofibroblast-like cells with tyrosine kinase receptor expression, as adjuncts to modern interventional therapies for the treatment of multivessel intraluminal pulmonary vein stenosis (PVS). We describe the 48- and 72-week outcomes among patients receiving imatinib mesylate with or without bevacizumab for multivessel intraluminal PVS. STUDY DESIGN: This single-arm, prospective, open-label US Food and Drug Administration approved trial enrolled patients with ≥2 affected pulmonary veins after surgical or catheter-based relief of obstruction between March 2009 and December 2014. Drug therapy was discontinued at 48 weeks, or after 24 weeks of stabilization, whichever occurred later. RESULTS: Among 48 enrolled patients, 5 had isolated PVS, 26 congenital heart disease, 5 lung disease, and 12 both. After the 72-week follow-up, 16 patients had stabilized, 27 had recurred locally without stabilization, and 5 had progressed. Stabilization was associated with the absence of lung disease (P = .03), a higher percentage of eligible drug doses received (P = .03), and was not associated with age, diagnosis, disease laterality, or number of veins involved. Survival to 72 weeks was 77% (37 of 48). Adverse events were common (n = 1489 total), but only 16 were definitely related to drug treatment, none of which were serious. CONCLUSION: Survival to 72 weeks was 77% in a referral population with multivessel intraluminal PVS undergoing multimodal treatment, including antiproliferative tyrosine kinase blockade. Toxicity specific to tyrosine kinase blockade was minimal.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Callahan R, Kieran MW, Baird CW, et al. Adjunct Targeted Biologic Inhibition Agents to Treat Aggressive Multivessel Intraluminal Pediatric Pulmonary Vein Stenosis. J Pediatr. 2018. PMID: 29576325. doi:10.1016/j.jpeds.2018.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。